From binary to gradient: EUS-RFA redefines primary aldosteronism therapy

IF 4.6 2区医学 Q1 PERIPHERAL VASCULAR DISEASE

Hypertension Research Pub Date : 2025-07-25 DOI:10.1038/s41440-025-02288-8

Zhixin Xu, Jing Chang

引用次数: 0

Abstract

EUS-RFA redefines PA treatment, shifting from a binary (surgery or drugs) to a gradient paradigm (ablation, drugs, surgery). Outcomes: EUS-RFA (FABULAS, Argentesi et al., The Lancet 2025): 75% biochemical remission, 43% clinical remission; medical treatment (PAMO criteria[9]): 52.9% biochemical response, 18.3% clinical response; surgery (PASO criteria[8]): 94% biochemical remission, 84% clinical remission.

Abstract Image

查看原文本刊更多论文

从二元到梯度：EUS-RFA重新定义了原发性醛固酮增多症治疗。

EUS-RFA重新定义了PA治疗，从二元模式（手术或药物）转变为梯度模式（消融、药物、手术）。结果：EUS-RFA (FABULAS， Argentesi等，The Lancet 2025): 75%生化缓解，43%临床缓解；内科治疗（PAMO标准[9]）：生化应答52.9%，临床应答18.3%；手术（PASO标准[8]）：94%生化缓解，84%临床缓解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hypertension Research 医学-外周血管病

CiteScore

7.40

自引率

16.70%

发文量

249

审稿时长

3-8 weeks

期刊介绍： Hypertension Research is the official publication of the Japanese Society of Hypertension. The journal publishes papers reporting original clinical and experimental research that contribute to the advancement of knowledge in the field of hypertension and related cardiovascular diseases. The journal publishes Review Articles, Articles, Correspondence and Comments.